Holen Sie sich die Stockscreener-App
28.79
0.17%
-0.05
Handel nachbörslich:
29.00
0.21
+0.73%
Schlusskurs vom Vortag:
$28.84
Offen:
$28.94
24-Stunden-Volumen:
67,941
Relative Volume:
0.64
Marktkapitalisierung:
$1.03B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+9.43%
1M Leistung:
+9.89%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$28.74
$29.34
1-Wochen-Bereich:
$26.71
$29.34
52-Wochen-Spanne:
$24.10
$29.53
Ceribell Inc Stock (CBLL) Company Profile
Firmenname
Ceribell Inc
Sektor
Branche
Telefon
(800) 436-0826
Adresse
360 N. PASTORIA AVENUE, SUNNYVALE
Vergleichen Sie CBLL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
28.79 | 1.03B | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
118.77 | 206.00B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
392.15 | 149.49B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
90.66 | 133.62B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
86.54 | 110.97B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
71.35 | 42.08B | 6.60B | 4.16B | 490.10M | 6.93 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-05 | Eingeleitet | BofA Securities | Buy |
| 2024-11-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Ceribell Inc Aktie (CBLL) Neueste Nachrichten
CeriBell: Healthcare Technology Stock With A Promising Growth Outlook (NASDAQ:CBLL) - Seeking Alpha
Ceribell appoints Rodenbush as CPO, Price as SVP of Marketing - TipRanks
Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing - The Manila Times
Ceribell Strengthens Leadership Team with Key AI Medical Device Executives | CBLL Stock News - StockTitan
Meet the biophysicist whose seizure-detection company is using AI to get a better read on people's brains - Fast Company
FY2024 EPS Estimates for CeriBell Reduced by William Blair - MarketBeat
William Blair Estimates CeriBell's Q1 Earnings (NASDAQ:CBLL) - MarketBeat
Ceribell revenue increases 48% to USD 17.2M in Q3 2024 - Medical Buyer
Ceribell, Inc. Reports Strong Q3 2024 Growth - Yahoo Finance
Ceribell price target raised to $31 from $30 at Canaccord - TipRanks
CeriBell (NASDAQ:CBLL) Price Target Raised to $31.00 at Canaccord Genuity Group - MarketBeat
CeriBell's (NASDAQ:CBLL) Quiet Period To End on November 20th - MarketBeat
CeriBell’s Quiet Period To End on November 20th (NASDAQ:CBLL) - Defense World
Ceribell Reports Third Quarter 2024 Financial Results - GlobeNewswire
CeriBell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs - GlobeNewswire
Ceribell Secures VA Authorization, Expands AI-Powered EEG Tech to Veterans Hospitals | CBLL Stock News - StockTitan
Q3 Earnings Estimate for CeriBell Issued By William Blair - Defense World
Brokerages Set CeriBell (NASDAQ:CBLL) PT at $31.00 - Defense World
Ceribell started with bullish ratings by J.P. Morgan, Canaccord - MSN
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Manila Times
FMR LLC Acquires New Stake in CeriBell Inc - GuruFocus.com
Ceribell initiated with a Buy at BofA on ‘differentiated AI algorithm’ - Yahoo Finance
Ceribell stock a buy as JPMorgan highlights disruptive tech in $3B seizure market - Investing.com Australia
Ceribell initiated with an Overweight at JPMorgan - MSN
Ceribell started with bullish ratings by J.P. Morgan, Canaccord (NASDAQ:CBLL) - Seeking Alpha
TD Cowen starts coverage on Ceribell stock with Buy, highlights innovative tech - Investing.com Canada
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
A&O Shearman advises on initial public offering of Ceribell, Inc. - A&O Shearman
Ceribell to Report Third Quarter 2024 Financial Results on November 12, 2024 - WV News
Ceribell’s stock soars 36% in trading debut after pricing IPO at top of range - MSN
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CeriBell: An Interesting EEG Play Going Public (NASDAQ:CBLL) - Seeking Alpha
TPG GP A, LLC Acquires New Stake in CeriBell Inc - GuruFocus.com
Ceribell EEG system linked to improved patient outcomes - Investing.com India
Ceribell EEG system linked to improved patient outcomes By Investing.com - Investing.com Australia
Ceribell director Juliet Tammenoms Bakker buys $4.03m in stock By Investing.com - Investing.com Australia
Ceribell director Juliet Tammenoms Bakker buys $4.03m in stock - Investing.com
New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG - PR Newswire
CeriBell closes upsized IPO - Medical Buyer
Finanzdaten der Ceribell Inc-Aktie (CBLL)
Es liegen keine Finanzdaten für Ceribell Inc (CBLL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.73%
0.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):